Clinical Trial

Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)

Investigator
Complete title:
A phase 1, open-label, safety and dosing study of autologous desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART) in subjects with active, anti-DSG3, mucosal-dominant pemphigus vulgaris
Trial phase:
Phase I
Study ID:
NCT04422912
Local study ID:
RG1121092
Summary:
Mucosal-dominant pemphigus vulgaris (mPV) is a B-cell mediated autoimmune disorder in which painful blisters are formed on the mucosal membrane, including the mouth, nose, throat, eyelids, anus, and genitals. This phase 1 study is being conducted to find the maximum tolerated dose and optimal fractionated infusion schedule of an investigational cell therapy, DSG3-CAART, that can be given to patients with mPV who are inadequately managed by standard therapies. DSG3-CAART may potentially lead to complete and durable remission of disease.
Trial keywords:
Immunotherapy
Enrollment status:
Recruiting
Trial eligibility
** For eligibility information, please click on the "Look up trial at NIH" link above **
Other eligibility criteria may apply.
Trial exclusions
** For exclusion information, please click on the "Look up trial at NIH" link above ** Other exclusion criteria may apply.
Learn more

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Contact us
David Qian

For more information about Fred Hutch and to schedule an appointment.